Navigation Links
'MicroRNA' could be key target for bowel cancer treatment
Date:4/14/2014

Scientists found that the molecule, called microRNA 135b, is a vital 'worker' employed by several important cancer genes to drive the growth of bowel cancers.

Drugs targeted at the microRNA could knock out the effects of multiple cancer-causing mutations at once, while tests for it could identify patients with the most aggressive disease, the researchers believe.

The research was carried out by an international team including scientists based at The Institute of Cancer Research, London, the University of Glasgow and Ohio State University in the US.

Scientists tested for microRNA 135b in 485 patients with bowel cancer and found that levels were at least four times as high in tumours as in healthy tissue, and that patients with the highest levels survived the least long.

They showed that blocking the microRNA stopped tumour growth in bowel cancer mouse models, and in half of them tumours regressed so dramatically they could no longer be seen by imaging. Mice didn't show any side-effects as a result of treatment.

The study is published today (Monday) in the prestigious journal Cancer Cell, with funding for the UK research team coming from the Kimmel Cancer Foundation, Cancer Research UK, The Marie Curie Actions Programme and a Scottish Senior Clinical Research Fellowship.

MicroRNAs are small strands of genetic material that regulate gene activity and are involved many cellular processes.

The study showed that a number of known cancer gene mutations, such as APC, PI3KCA, SRC and p53, exercise their effects through microRNA 135b.

Although treatments targeting bowel cancer mutations have been developed, patients often develop resistance. Inhibiting microRNA 135b could be an exciting way to attack cancers without resistance occurring by blocking the effects of multiple cancer-causing mutations simultaneously.

The findings also suggest that testing levels of microRNA 135b could help identify patients likely to develop aggressive bowel cancer, and who might need the most intensive treatment.

Lead author Dr Nicola Valeri, Leader of the Gastrointestinal Cancer Biology and Genomics Team at The Institute of Cancer Research, London, said:

"We have shown that a specific microRNA can drive the development of bowel cancers and is a key 'worker' responsible for putting into action the instructions from many cancer-causing mutations. Patients with the highest levels of this molecule have the most difficult-to-treat cancers, and inhibiting the molecule in mice prevents tumours from growing. Although the research is at an early stage, our findings may have an important impact in the way we treat patients with bowel cancer in the future."

Professor Paul Workman, Deputy Chief Executive of The Institute of Cancer Research, London, said: "This work sheds light on the important role of microRNAs in bowel cancer and opens up a potentially exciting new avenue for cancer treatment. It also gives us a marker of disease that might prove valuable in the clinic to predict which patients have a more aggressive cancer.

"MicroRNAs play a vital role in the cells in our body, both in normal functions and in disease. We have known for a while that microRNAs are important in cancer, but their diversity of roles has meant it's been difficult to target them with drugs without causing toxic side-effects. This particular RNA has a huge advantage that might allow us to avoid this toxicity, because it is found in very low levels in normal tissue and in high levels in cancer."

Professor Owen Sansom, Deputy Director of The Cancer Research UK Beatson Institute at Glasgow University, said: "This exciting work shows a single microRNA can control multiple pathways that go wrong in colon cancer and offers the hope that in the future this could be targeted in patients that have colon cancer."


'/>"/>

Contact: Graham Shaw
graham.shaw@icr.ac.uk
44-207-153-5380
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. A microRNA prognostic marker identified in acute leukemia
2. Pint-size microRNAs show promise against weighty problem, researchers say
3. MicroRNAs can convert normal cells into cancer promoters
4. Hepatitis B virus promotes oncogenesis through microRNA modulation
5. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
6. Atherosclerosis: Specific microRNAs promote inflammation
7. Moffitt Cancer Center researchers say 1 specific microrna promotes tumor growth and cancer spread
8. New papers identify a microRNA that drives both cancer onset and metastasis
9. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
10. Versatile microRNAs choke off cancer blood supply, suppress metastasis
11. MicroRNA-31 might predict lung-cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... August 18, ... ... d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of ... entered into a definitive agreement to purchase Unitrans International Corporation, a division ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... McLean, VA (PRWEB) , ... August 18, 2017 ... ... offers asset protection services and financial consultations to communities throughout the greater DC ... Semper K9 with the goal of rescuing local animals and training them to ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance Group, a Miami ... southern Florida, is working to support the Take Stock In Children Foundation during ... families. , The Take Stock In Children Foundation (TSC) offers guidance and assistance ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance management ... spearheading a regional charity campaign organized to provide support to Christina Upchurch and her ... year, Christina and her children returned from out of town to find her husband ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... SINGAPORE , July 27, 2017  Radium Medical Aesthetics, a ... LASEMD, designed to delay aging by effectively addressing several skin conditions ... the skin to become rougher and more fragile. The skin becomes ... the unavoidable exposure to the harmful UV rays from the sun ... hyperpigmentation. ...
(Date:7/26/2017)... , July 26, 2017 The Galien ... Prix Galien USA Award Nominees. Counted ... Prix Galien Award recognizes outstanding biomedical and technology product achievement ... To qualify, each candidate must be U.S. Food ... five years and demonstrate tremendous potential to impact human health. ...
Breaking Medicine Technology: